Early Access — free while we kick the tires
EdgarHawk

CASAMENTO CHARLES J

Director

Director
1 filing analyzed · 1 company · Latest 2024-09-11

Companies

Company Buys Sells Direction
RELMADA THERAPEUTICS, INC. RLMD 1 0 Net buying

Activity

September 2024
high
Buy
13,000 shares
$33,280
Significance 6/10

Director Casamento buys 13,000 shares of RLMD at $2.56; 3 other insiders bought in past 14 days amid -35.4% annual revenue decline.

Charles Casamento, a director, initiated a position in Relmada with a 13,000-share purchase at $2.56 on 2024-09-09, totaling $33,280.00. The transaction is notable because it coincides with a cluster pattern: 3 other insiders also bought within the past 14 days, suggesting coordinated or signal-driven purchasing activity at this price level. However, the company's fundamentals are strained—annual revenue contracted -35.4% year-over-year, and the firm posted a $-17.8M net loss on minimal revenue of $682.00 in the latest quarter. The stock trades -55.6% below its 52-week high, raising questions about whether directors are responding to genuine operational recovery prospects or simply opportunistic entry into a depressed asset price. This clustering warrants attention to determine whether new catalysts or strategic initiatives justify the simultaneous accumulation.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access